Health
China’s Sinovac reports mixed findings in early coronavirus vaccine trials – The Washington Post
Study found the vaccine candidate produced a quick immune response but lower levels of antibodies than in recovered coronavirus patients.
These early results put Sinovac on the back foot to prove its vaccine is effective in ongoing Phase 3 trials.
That is a concern, said Thomas Campbell, associate dean for clinical research at the University of Colorado, of the low antibody levels in Sinovacs Phase 2 trial. Its an important point here, in terms of comparing this vaccine to, for instance, the Moderna and Pfizer vaccines.
As the world awaits a coronavirus vaccine, some in China get early doses
Indonesia, the worlds fourth-most populous…
-
Noosa News19 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General19 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
General10 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging
-
Noosa News18 hours agoMurray Watt claims Queensland will follow Sussan Ley and ditch net zero by 2050